If you’ve been told you have the hepatitis C virus (HCV), you should know you’re not alone. A silent epidemic, chronic hepatitis C affects an estimated 2.4 million Americans, according to the ...

Hepatitis C virus (HCV) infection is highly associated with the development of metabolic dysfunction-associated steatotic ...

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for a label expansion for MAVYRET ...

Six patients were found to have hepatitis C viremia ... The anesthesiology assistant contracted HCV from Patient 1 and subsequently transmitted the virus, during the incubation stage of his ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

Patients infected with Hepatitis C Virus (HCV) often present with rheumatic symptoms, but its link to rheumatoid arthritis ...

FDA approved a label expansion for Mavyret for the treatment of acute hepatitis C virus, according to a press release from ...

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for ...

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus: North Chicago Saturday, June 14, 2025, 11:00 Hrs [IST] AbbVie announced tha ...

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...